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Abstract
Ankylosing spondylitis (AS) is associated with accelerated atherosclerosis and enhanced cardio-
vascular morbidity and mortality compared to the general population. The mechanisms and me-
diators of this phenomenon have not been fully explained, but an expanding body of evidence 
demonstrates that increased cardiovascular risk in AS is heralded by endothelial dysfunction. We 
performed a literature review using the PubMed database from the year 2006 up to 2018. In this 
article we review the epidemiology, current evidence for impaired endothelial function, potential 
mechanisms and markers controlling this dysfunction, and finally we summarize the data regarding 
the efficacy of pharmacotherapy in reducing endothelial dysfunction in patients suffering from AS.
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Introduction
Ankylosing spondylitis (AS), one of the most preva-
lent chronic autoinflammatory diseases from the spon-
dyloarthritis (SpA) group, is associated with accelerated 
atherosclerosis and enhanced cardiovascular morbidity 
and mortality compared to the general population, which 
cannot be fully explained by the presence of traditional 
cardiovascular risk factors. To date, the mechanisms and 
mediators of increased non-traditional risk are not fully 
elucidated. Efforts to understand this phenomenon have 
often focused on the endothelium, which serves as an in-
terface for multiple overlapping risk factors and has been 
proposed to represent an initial step in the pathogenesis 
and maintenance of all stages of atherogenesis – from 
plaque formation to plaque rupture and thrombogene-
sis. In this article we review the epidemiology, discuss the 
evidence for impaired endothelial function and potential 
mechanism controlling this state, and finally we summa-
rize the data regarding the efficacy of drugs in reducing 
endothelial dysfunction in patients with AS.
Ankylosing spondylitis
Ankylosing spondylitis is a chronic, systemic, autoin-
flammatory disease of the spine and sacroiliac joints with 
variable involvement of peripheral joints and non-articular 
organs such as the eye, gastrointestinal tract, skin, heart, 
and vascular system. The onset of AS is most often during 
the third decade of life, more frequently in males than in 
females, and results in serious impairment of spinal mobil-
ity and physical function, which has an adverse impact on 
quality of life. The prevalence of AS is generally assessed 
to be between 0.1% and 1.4% globally [1]. Ankylosing 
spondylitis has a strong genetic predisposition – genetic 
risk factors contribute to 80–90% of the susceptibility to 
the disease, and the main risk factor is the presence of 
HLA-B27 antigen, an MHC class I molecule. Although the 
mechanisms of AS onset remain incompletely understood, 
all of the most often discussed hypothesis of the potential 
roles of HLA-B27 in the pathogenesis of AS lead to the ab-
normal production of proinflammatory cytokines – five of 
which are of particular interest in the initiation and perpet-
uation of inflammation in AS: TNF-α (which probably plays 
a key role in the generation and chronicity of systemic in-
flammation), IL-1, IL-6, IL-17, and IL-23 [2].
Epidemiology of cardiovascular events 
in ankylosing spondylitis
Standardized mortality ratios (SMRs) in patients with 
AS are higher than those in the general population (1.6–
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1.9), and often premature mortality is due to cardiovascu-
lar events [3–6]. In addition to higher SMRs, AS patients 
have an increased rate of cardiovascular morbidity [6–8]. 
Data on cardiovascular incidence in AS individuals 
are limited and heterogeneous. Several studies have 
shown that ischemic heart disease, cerebrovascular ac-
cidents and peripheral artery disease are more common 
in patients with AS than in the general population [9]. 
To date, most (but not all) studies have reported certain 
levels of increased risk for different cardiovascular dis-
eases in AS patients compared with non-AS subjects. 
Eriksson et al. [9], in a cohort study, demonstrated that 
patients with AS are at a 30–50% enhanced risk of acute 
coronary, cerebrovascular, and thromboembolic events 
compared with the general population, which cannot be 
fully explained by traditional cardiovascular risk factors 
such as smoking, obesity, hyperlipidemia or dyslipid-
emia, arterial hypertension, and diabetes.
Assessment of endothelial function
In clinical trials endothelial function is typically as-
sessed by measuring changes in vasomotor tone in 
response to various stimuli. The most widely used non- 
invasive method is flow-mediated dilation (FMD) – an 
ultrasound technique that measure changes in brachial 
artery diameter in response to shear stress-induced vaso-
dilation, which is an endothelium-dependent process. In 
some studies, FMD has been demonstrated to correlate 
with biomarkers for subclinical atherosclerosis and future 
cardiovascular events, although there are a number of 
studies in which no such correlation has been found. One 
possible explanation of this inconsistency is the fact that 
FMD is a technically challenging method and may be in-
fluenced by many confounding variables – a negative cor-
relation between the percentage flow mediated dilation 
and baseline artery size is recognized as a fundamental 
scaling problem leading to biased estimates [10]. Anoth-
er challenge of FMD is variability across centers and the 
need for a well-trained and experienced operator to per-
form this examination [10]. 
Endothelial function could also be evaluated non-in-
vasively by using laser Doppler imaging to measure mi-
crovascular perfusion in the cutaneous microcirculation 
– this technique has not yet been widely applied and val-
idated in patients with AS. There have been some con-
cerns that assessment of conduit artery function (as-
sessed by FMD) is insufficient in reflecting what exactly 
is happening in the endothelium of microcirculation. 
An expanding body of evidence demonstrates that 
microvascular dysfunction contributes to progression of 
target organ damage [11], and measuring microvascu-
lar vasodilation seems to be a promising research tool 
in individuals suffering from AS. It is worth mentioning 
that numerous molecules including adhesion molecules 
– intercellular adhesion molecule 1 (ICAM-1), vascular 
cell adhesion molecule 1 (VCAM-1), E-selectin, P-selectin; 
nitric oxide (NO); endothelin 1 (ET-1), asymmetric dime- 
thylarginine (ADMA), an endogenous endothelial nitric 
oxide synthase (eNOS) inhibitor, inflammatory cyto-
kines, regulators of thrombosis, and indicators of endo-
thelial damage and repair – endothelial progenitor cells 
(EPCs), platelet microparticles, vaspin, and apelin have 
been proposed as biomarkers for endothelial dysfunc-
tion, but to date the clinical significance of most of these 
biomarkers remains uncertain. 
To explain the relationship between indicators of 
vascular dysfunction, conduit artery stiffness and en-
hanced cardiovascular risk in AS patient markers of 
endothelial dysfunction are correlated with traditional 
cardiovascular risk factors (including hypertension, dys-
lipidemia, insulin resistance, diabetes mellitus, smoking, 
obesity), plasma markers of inflammation used in clin-
ical practice (C-reactive protein – CRP, erythrocyte sed-
imentation rate – ESR), indicators of arterial stiffness 
(measured by pulse wave velocity – PWV, and aortic 
augmentation index – AIx), subclinical atherosclerosis 
examined by ultrasonography of carotid arteries (ca-
rotid intima-media thickness – cIMT), and AS disease 
activity scales (Ankylosing Spondylitis Disease Activity 
Score – ASDAS, Bath Ankylosing Spondylitis Functional 
Index – BASFI, and Bath Ankylosing Spondylitis Disease 
Activity Index – BASDAI).
Endothelial dysfunction
The endothelium – the inner lining of blood ves-
sels – plays a critical and active role in the regulation of 
vascular tone and growth, smooth muscle migration, 
cellular adhesion and cellular interactions, thrombogen-
esis, thrombolysis, and maintenance of homeostasis 
between pro- and antithrombotic factors (Fig. 1). Impaired 
endothelial function is a state of endothelium which re-
fers to its failure to cope with these physiological func-
tions and is expressed as an upregulation of cellular adhe-
sion molecules, compromised barrier function, increased 
vascular tone, and reduced resistance to thrombosis. In 
a number of studies endothelial dysfunction is restricted 
to endothelial vasomotor dysfunction and defined as an 
imbalance between vasodilating and vasoconstricting 
stimuli (both chemical and physical) acting on the endo-
thelium or as an impaired ability of the artery to dilate in 
response to those stimuli, mainly caused by loss of endo-
thelium-derived nitric oxide (NO) [12–14]. 
Because longstanding endothelial dysfunction pro-
motes structural damage of the vascular wall and NO 
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is one of the endothelial-derived factors with the stron-
gest antiatherogenic effect, endothelial dysfunction 
is a major pathophysiological mechanism that leads 
towards the development of atherosclerotic cardiovas-
cular disease [15]. Therefore, endothelial dysfunction 
represents a key step in the initiation, maintenance, and 
progression of atherosclerosis [16, 17] and may serve 
as an important marker responsible for atherosclerosis 
and future cardiovascular events [18]. Endothelial dys-
function has been reported to predate clinically obvious 
vascular pathology by years [19] and is also recognized 
as a predictor of adverse cardiovascular outcomes in the 
general population [20–22]. 
An increased prevalence of endothelial dysfunction 
in AS has been proven in several studies [23–25] along 
with the rising incidence of subclinical atherosclerosis 
[26]. Patients with AS often manifest endothelial dys-
function early in the course of the disease, which might 
be combined with traditional cardiovascular risk factors 
[27]; however, the association between inflammation, 
atherosclerosis, vascular dysfunction, and AS is multi-
factorial and still not entirely understood. 
The link between endothelial dysfunction, 
atherosclerosis, and enhanced cardiovascular 
risk in patients with ankylosing spondylitis
Atherosclerosis is a chronic, progressive, inflamma-
tory disease with a long asymptomatic phase. Mech-
anisms involved in systemic inflammation have been 
shown to contribute to atherosclerosis, which is the 
leading cause of enhanced cardiovascular risk and one 
of the most important causes of mortality and morbidity 
in the cardiovascular system [28]. Endothelial dysfunc-
tion is an early, initially reversible step in the develop-
ment of atherosclerosis [29], and atherogenesis begins 
at sites of endothelial injury. What is more, impaired en-
dothelial function and inflammation per se play a role in 
all stages of atherosclerosis – from plaque formation to 
instability and eventually plaque rupture [15]. 
A great number of proinflammatory molecules such 
as CRP, fibrinogen, and cytokines (TNF-α, IL-1, IL-6, IL-10, 
IL-17, IL-23) are involved in this process. Therefore, bio-
markers of endothelial dysfunction and inflammation 
are used as surrogate markers of subclinical atheroscle-
rosis [30, 31]. There is also a considerable rationale that 
inflammation per se can deteriorate lipid profile.
Disturbances in lipid levels, especially lowering of 
serum high-density lipoprotein cholesterol (HDLc) and 
increasing concentrations of triglycerides and low-den-
sity lipoproteins cholesterol (LDLc), has been proven to 
accelerate atherosclerosis. In several studies, reduction 
in HDLc was more frequently found in AS than in healthy 
controls [31]. This phenomenon might be at least par-
tially responsible for enhanced cardiovascular risk in AS 
subjects. In addition, the current data indicate that vasa 
vasorum neovascularization is attenuated by inflamma-
tory processes in the vascular wall and is strictly con-
nected with accelerated atherogenesis [31]. 
Patients with AS present an altered profile of differ-
ent endogenous regulators of endothelial integrity and 
angiogenic factors such as ET-1, EPCs, proinflammatory 
cytokines, and adhesion molecules – biomarkers that 
offer an opportunity to study the relationship between 
the development of asymptomatic atherosclerosis and 
increased cardiovascular risk, and may help to identify 
high-risk individuals who may benefit from targeted 
therapy to prevent further cardiovascular events.
Fig. 1. Schematic presentation of the key functions of normal and dysfunctional endothelium.
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Markers of endothelial dysfunction  
in patients with ankylosing spondylitis
A number of biomarkers presumably involved in 
atherosclerosis in AS have been studied and are pre-
sented in Table I. A considerable number of studies have 
reported that asymmetric dimethylarginine (ADMA), 
an endogenous NO inhibitor, is significantly increased 
in the blood of AS patients [32–36] and contributes to 
higher cardiovascular risk [36]. In a study performed by 
Przepiera-Będzak et al. [37] serum endothelin 1 (ET-1) 
concentrations were lower in AS patients than in con-
trols; however, Sari et al. [34] did not show any statis-
tically significant difference in its levels. Endothelial 
progenitor cell (EPC) depletion in AS inversely correlated 
with disease duration, activity, and inflammation and 
positively correlated with endothelial dysfunction found 
in FMD and cIMT [38, 39]. 
The levels of adhesion molecules ICAM and VCAM 
were positively correlated with predisposing factors for 
cardiovascular disease [40], and IL-8 has been shown 
to be strongly correlated with clinical markers of dis-
ease activity (ASDAI and BASDAS) in patients with AS 
who are naive for anti-TNF agents [40]. Wang et al. [41] 
found that in AS patients serum levels of vaspin were 
decreased and associated substantially with impaired 
endothelial function measured by FMD. 
Circulating endothelial microparticles (EMP) and 
platelet microparticles (PMP), known to be indicators 
and mediators of vascular damage, were not signifi-
cantly elevated in AS patients without classical cardio-
vascular factors, but were considerably downregulated 
in patients treated with TNF inhibitors compared with 
subjects treated with NSAIDs and healthy controls [42]. 
This finding suggests that anti-TNF therapy may have 
a beneficial effect on endothelium homeostasis in AS. 
However, Orüm et al. [43] detected platelet activation 
reflected by high levels of platelet-monocyte complexes 
(PMC) and soluble CD40L (sCD40L) in AS patients but 
did not show any improvement of platelet activation ex-
pressed as levels of PMC, platelet-neutrophil complexes, 
P-selectin (CD62P), soluble E-selectin, and sCD40L in 
AS patients after anti-TNF therapy. Impaired FMD, in-
creased cIMT and PWV in AS subjects compared with 
healthy controls were found by Bodnár et al. [24]. 
A study conducted by Sari et al. [23] demonstrated 
significantly lower FMD but did not show a difference in 
IMT of the common carotid artery in AS patients in com-
parison with healthy individuals. Erre et al. [32] did not 
show any statistically significant differences between 
AS and controls with regard to FMD, cIMT, and PWV.
The effect of drugs
Increased cardiovascular risk in AS patients and the 
fact that endothelial dysfunction is reversible after a re-
duction in atherosclerotic risk factor by life-style mod-
ifications and pharmacological treatment [44] provide 
a strong rationale for early therapeutic intervention. 
Table I. Proposed biomarkers for endothelial dysfunction in ankylosing spondylitis
Biomarker References Proposed mechanism of endothelial dysfunction in AS
ADMA Erre et al. 2011
Kemeny-Beke et al. 2010
Sari et al. 2009
Sulicka et al. 2017
Berg et al. 2015
Reduction of NO concentration, impaired vasomotion, platelet 
aggregation, vascular wall remodelling
ET-1 Przepiera-Będzak et al. 2016 Vasoconstriction, vascular wall remodelling
EPCs Verma et al. 2015
Verma et al. 2017
Vascular wall remodelling, impaired endothelial repair
ICAM, VCAM Azevedo et al. 2013 Increased permeability, increased leukocyte adhesion
IL-8 Azevedo et al. 2013 Increased leukocyte adhesion and migration, vascular wall 
remodelling, angiogenesis
EMP, PMP Sari et al. 2012 Vascular wall remodelling, vascular damage, impaired  
endothelial repair
PMC Orüm et al. 2012 Platelet activation and aggregation, prothrombotic state
sCD40L Orüm et al. 2012 Platelet activation and aggregation, prothrombotic state
P-selectin,  
E-selectin
Orüm et al. 2012 Increased permeability, increased leukocyte adhesion
AS – ankylosing spondylitis, ADMA – asymmetric dimethylarginine, NO – nitric oxide, ET-1 – endothelin 1, EPCs – endothelial progenitor 
cells, ICAM – intercellular adhesion molecule 1, VCAM – vascular cell adhesion molecule 1, IL-8 – interleukin 8, EMP – endothelial micropar-
ticles, PMP – platelet microparticles, PMC – platelet-monocyte complexes, sCD40L – soluble CD40L.
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A beneficial effect of infliximab on endothelial dysfunc-
tion in non-diabetic AS patients, manifested by a reduc-
tion in level of biomarkers of endothelial cell activation 
such as soluble E-selectin and soluble VCAM-1, was ob-
served by Genre et al. [45]. Also, Syngle et al. [46] found 
that infliximab improves both endothelial dysfunction 
measured by FMD and inflammatory AS activity in previ-
ously anti-TNF-naive patients. 
Endothelial dysfunction evaluated by laser Doppler 
fluxmetry after iontophoresis of acetylcholine and im-
paired capillary recruitment obtained by videomicroscopy 
improved significantly after etanercept, another TNF-in-
hibitor treatment [47]. Rosuvastatin was associated with 
an improvement in FMD, arterial stiffness, carotid plaque 
regression, inflammatory disease activity, and dyslipid-
emia [48, 49]. Spironolactone treatment was found to be 
associated with an improvement in FMD and inflamma-
tory disease activity [50].
Conclusions
Patients with AS are at higher risk for cardiovascu-
lar morbidity and mortality than the general population. 
Accelerated atherogenesis represents the pathogenetic 
link between cardiovascular comorbidity and inflamma-
tory rheumatic diseases. Growing evidence demonstrates 
that even in the absence of clinically evident atheroscle-
rosis this enhanced cardiovascular risk is reflected early 
in measures of endothelial dysfunction. The endothelium 
seems to serve as an integrating platform of assessing 
cardiovascular risk, and there is a strong rationale to in-
vestigate its role and significance in this process. 
This research offers a great opportunity to elucidate 
the relationship between the asymptomatic atherosclero-
sis and elevated cardiovascular risk and may help identify 
individuals with AS, who may benefit from targeted ther-
apy to prevent clinically evident cardiovascular disease.
The authors declare no conflict of interest.
References
1.  Dean LE, Jones GT, MacDonald AG, et al. Global prevalence 
of ankylosing spondylitis. Rheumatology (Oxford) 2014; 53: 
650-657.
2.  Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377: 
2127-2137.
3.  Lehtinen K. Mortality and causes of death in 398 patients 
admitted to hospital with ankylosing spondylitis. Ann Rheum 
Dis 1993; 52: 174-176.
4.  Zochling J, Braun J. Mortality in ankylosing spondylitis. Clin 
Exp Rheumatol 2008; 26 (5 Suppl 51): S80-84.
5.  Agca R, Heslinga SC, van Halm VP, et al. Atherosclerotic cardio-
vascular disease in patients with chronic inflammatory joint 
disorders. Heart 2016; 102: 790-795.
6.  Bengtsson K, Forsblad-d’Elia H, Lie E, et al. Are ankylosing 
spondylitis, psoriatic arthritis and undifferentiated spondy-
loarthritis associated with an increased risk of cardiovascular 
events? A  prospective nationwide population-based cohort 
study. Arthritis Res Ther 2017; 19: 102.
7.  Bremander A, Petersson IF, Bergman S, et al. Population-based 
estimates of common comorbidities and cardiovascular dis-
ease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 
2011; 63: 550-556. 
8.  Wright KA, Crowson CS, Michet CJ, et al. Time trends in in-
cidence, clinical features, and cardiovascular disease in an-
kylosing spondylitis over three decades: a population-based 
study. Arthritis Care Res (Hoboken) 2015; 67: 836-841.
9.  Eriksson JK, Jacobsson L, Bengtsson K, et al. Is ankylosing 
spondylitis a risk factor for cardiovascular disease, and how 
do these risks compare with those in rheumatoid arthritis? 
Ann Rheum Dis 2017; 76: 364-370.
10. Thijssen DHJ, Black MA, Pyke KE, et al. Assessment of 
flow-mediated dilation in humans: a  methodological and 
physiological guideline. Am J Physiol Heart Circ Physiol 2011; 
300: H2-12. 
11.  Cooper LL, Palmisano JN, Benjamin EJ, et al. Microvascular 
function contributes to the relation between aortic stiffness 
and cardiovascular events: the Framingham Heart Study. Circ 
Cardiovasc Imaging 2016; 9: e004979.
12.  Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity 
in the human coronary circulation. Impact of risk factors for 
coronary atherosclerosis. Clin Invest 1995; 95: 1747-1755. 
13.  Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, 
pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 
109-142. 
14.  Kugiyama K, Yasue H, Ohgushi M, et al. Deficiency in nitric 
oxide bioactivity in epicardial coronary arteries of cigarette 
smokers. J Am Coll Cardiol 1996; 28: 1161-1167. 
15.  Mudau M, Genis A, Lochner A, et al. Endothelial dysfunction: 
the early predictor of atherosclerosis. Cardiovasc J Afr 2012; 
23: 222-231. 
16.  Eren E, Yilmaz N, Aydin O. Functionally defective high-density 
lipoprotein and paraoxonase: A  couple for endothelial dys-
function in atherosclerosis. Cholesterol 2013; 2013: 792090.
17.  Behrendt D, Ganz P. Endothelial function: From vascular biolo-
gy to clinical applications. Am J Cardiol 2002; 90: L40-L48. 
18.  Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: 
A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 
2003; 23: 168-175. 
19.  Munzel T, Sinning C, Post F, et al. Pathophysiology, diagnosis 
and prognostic implications of endothelial dysfunction. Ann 
Med 2008; 40: 180-196. 
20.  Yeboah J, Crouse JR, Hsu F-C, et al. Brachial flow-mediated di-
lation predicts incident cardiovascular events in older adults: 
the Cardiovascular Health Study. Circulation 2007; 115: 2390-
2397. 
21.  Schächinger V, Britten MB, Zeiher AM. Prognostic impact of 
coronary vasodilator dysfunction on adverse long-term out-
105Endothelial dysfunction in patients with ankylosing spondylitis
Reumatologia  2019; 57/2
come of coronary heart disease. Circulation 2000; 101: 1899-
1906. 
22.  Heitzer T, Schlinzig T, Krohn K, et al. Endothelial Dysfunction, 
Oxidative Stress, and Risk of Cardiovascular Events in Patients 
With Coronary Artery Disease. Circulation 2001; 104: 2673-
2678. 
23.  Sari I, Okan T, Akar S, et al. Impaired endothelial function in 
patients with ankylosing spondylitis. Rheumatology (Oxford) 
2006; 45: 283-286. 
24.  Bodnar N, Kerekes G, Seres I, et al. Assessment of subclini-
cal vascular disease associated with ankylosing spondylitis. 
J Rheumatol 2011; 38: 723-729. 
25.  Deyab G, Hokstad I, Whist JE, et al. Methotrexate and anti-tu-
mor necrosis factor treatment improves endothelial function 
in patients with inflammatory arthritis. Arthritis Res Ther 
2017; 19: 232. 
26.  Sharma SK, Prasad KT, Handa R, et al. Increased prevalence 
of subclinical atherosclerosis in ankylosing spondylitis. Indian 
J Rheumatol 2015; 10: 53-57.
27.  Castaneda S, Nurmohamed MT, Gonzalez-Gay MA. Cardiovas-
cular disease in inflammatory rheumatic diseases. Best Pract 
Res Clin Rheumatol 2016; 30: 851-869. 
28.  Papagoras C, Voulgari P V, Drosos AA. Atherosclerosis and 
cardiovascular disease in the spondyloarthritides, particularly 
ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheu-
matol 2013; 31: 612-620.
29.  Celermajer DS. Endothelial dysfunction: Does it matter? Is it 
reversible? J Am Coll Cardiol 1997; 30: 325-333. 
30.  Steyers CM III, Miller FJJ. Endothelial dysfunction in chronic 
inflammatory diseases. Int J Mol Sci 2014; 15: 11324-11349. 
31.  Azevedo VF, Pecoits-Filho R. Atherosclerosis and endothelial 
dysfunction in patients with ankylosing spondylitis. Rheuma-
tol Int 2010; 30: 1411-1416. 
32.  Erre GL, Sanna P, Zinellu A, et al. Plasma asymmetric dimeth-
ylarginine (ADMA) levels and atherosclerotic disease in an-
kylosing spondylitis: a cross-sectional study. Clin Rheumatol 
2011; 30: 21-27. 
33.  Kemeny-Beke A, Gesztelyi R, Bodnar N, et al. Increased pro-
duction of asymmetric dimethylarginine (ADMA) in ankylos-
ing spondylitis: association with other clinical and laboratory 
parameters. Joint Bone Spine 2011; 78: 184-187.
34.  Sari I, Kebapcilar L, Alacacioglu A, et al. Increased levels of 
asymmetric dimethylarginine (ADMA) in patients with anky-
losing spondylitis. Intern Med 2009; 48: 1363-1368.
35.  Sulicka J, Surdacki A, Korkosz M, et al. Endothelial dysfunc-
tion is independent of inflammation and altered CCR7 T cell 
expression in patients with ankylosing spondylitis. Clin Exp 
Rheumatol 2017; 35: 844-849.
36.  Berg IJ, Van Der Heijde D, Dagfinrud H, et al. Disease activity in 
ankylosing spondylitis and associations to markers of vascu-
lar pathology and traditional cardiovascular disease risk fac-
tors: A cross-sectional study. J Rheumatol 2015; 42: 645-653.
37.  Przepiera-Będzak H, Fischer K, Brzosko M. Serum interleu-
kin-18, fetuin-A, soluble intercellular adhesion molecule-1, 
and endothelin-1 in ankylosing spondylitis, psoriatic arthritis, 
and SAPHO syndrome. Int J Mol Sci 2016; 17: 1255.
38.  Verma I, Syngle A, Krishan P. Endothelial progenitor cell biol-
ogy in ankylosing spondylitis. Int J Rheum Dis 2015; 18: 336-
340. 
39.  Verma I, Syngle A, Krishan P, et al. Endothelial Progenitor Cells 
as a Marker of Endothelial Dysfunction and Atherosclerosis in 
Ankylosing Spondylitis: A Cross-Sectional Study. Int J Angiol 
2017; 26: 36-42. 
40.  Azevedo VF, Faria-Neto JR, Stinghen A, et al. IL-8 but no other 
biomarkers of endothelial damage is associated with disease 
activity in patients with ankylosing spondylitis without treat-
ment with anti-TNF agents. Rheumatol Int 2013; 33: 1779-
1783.
41.  Wang HH, Wang QF. Low vaspin levels are related to endothe-
lial dysfunction in patients with ankylosing spondylitis. Braz 
J Med Biol Res 2016; 49: S0100-879X2016000700705.
42.  Sari I, Bozkaya G, Kirbiyik H, et al. Evaluation of circulating en-
dothelial and platelet microparticles in men with ankylosing 
spondylitis. J Rheumatol 2012; 39: 594-599.
43.  Orüm H, Pamuk GE, Pamuk ON, et al. Does anti-TNF therapy 
cause any change in platelet activation in ankylosing spon-
dylitis patients? A comparative study. J Thromb Thrombolysis 
2012; 33: 154-159.
44.  Kitta Y, Obata J, Nakamura T, et al. Persistent Impairment of 
Endothelial Vasomotor Function Has a  Negative Impact on 
Outcome in Patients With Coronary Artery Disease. J Am Coll 
Cardiol 2009; 53: 323-330.
45.  Genre F, Lopez-Mejias R, Miranda-Filloy JA, et al. Anti-TNF-alpha 
therapy reduces endothelial cell activation in non-diabetic 
ankylosing spondylitis patients. Rheumatol Int 2015; 35: 2069-
2078.
46.  Syngle A, Vohra K, Sharma A, et al. Endothelial dysfunction 
in ankylosing spondylitis improves after tumor necrosis fac-
tor-alpha blockade. Clin Rheumatol 2010; 29: 763-770.
47.  van Eijk IC, Peters MJL, Serne EH, et al. Microvascular function 
is impaired in ankylosing spondylitis and improves after tu-
mour necrosis factor alpha blockade. Ann Rheum Dis 2009; 
68: 362-366.
48.  Garg N, Krishan P, Syngle A. Rosuvastatin improves endotheli-
al dysfunction in ankylosing spondylitis. Clin Rheumatol 2015; 
34: 1065-1071.
49.  Ikdahl E, Hisdal J, Rollefstad S, et al. Rosuvastatin improves 
endothelial function in patients with inflammatory joint dis-
eases, longitudinal associations with atherosclerosis and ar-
teriosclerosis: Results from the RORA-AS statin intervention 
study. Arthritis Res Ther 2015; 17: 279.
50.  Syngle A, Vohra K, Khichi D, et al. Spironolactone improves 
endothelial dysfunction in ankylosing spondylitis. Clin Rheu-
matol 2013; 32: 1029-1036.
